Clinical Scorecard: Combination of Anti-PD-1 Monoclonal Antibody and Chemotherapy in Treating Porocarcinoma: A Case Study and Review of Existing Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Elderly individuals (e.g., 65 years and older) with porocarcinoma
Care Setting
Key Highlights
high_tumor_mutational_burden
Guideline-Based Recommendations
Diagnosis
Management
Combination therapy with anti-PD-1 monoclonal antibody and chemotherapy may be considered.
Consider follow-up treatments after acquired resistance, such as alternative immunotherapies or targeted therapies.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Initial response to combination therapy followed by acquired resistance; patient had multiple comorbidities including coronary artery disease and diabetes.
Clinical Best Practices
Utilize immunohistochemistry for accurate diagnosis.
Consider patient comorbidities when planning treatment.
Monitor for adverse events during treatment, including gastrointestinal symptoms and myelosuppression.
